


Searching News Database: TH9507
HSMN NewsFeed - 1 Oct 2007
Theratechnologies Reports Positive 52-Week Phase 3 Results for its Lead Drug Candidate Tesamorelin
Theratechnologies Reports Positive 52-Week Phase 3 Results for its Lead Drug Candidate Tesamorelin
HSMN NewsFeed - 31 Jan 2007
Theratechnologies Launches Confirmatory Phase 3 Trial Testing TH9507 in HIV-Associated Lipodystrophy
Theratechnologies Launches Confirmatory Phase 3 Trial Testing TH9507 in HIV-Associated Lipodystrophy
Additional items found! 4
Members Archive contains
4 additional stories matching:
TH9507
(Password required)
TH9507
(Password required)
